ulcerative colitis and Crohn's disease
Gastroenterology · 2021–2021
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Induction dose for patients weighing less than 40 kg with moderate to severe ulcerative colitis or severe Crohn disease. | Nov 2021 | Recommended with restriction | unclear |
What the PBS pays
$487M in government benefit over 2024–25, across 923,275 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
| vedolizumab | $182.8M |
| mesalazine | $62M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.